Pan Cancer T announces that Dr. Helen Tayton-Martin has joined its board as an independent director
Dr. Helen Tayton-Martin joins our board, bringing decades of leadership in TCR-T cell therapy and biotech growth.
Awarded the Seal of Excellence from the European Commission
February 27, 2024
Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence.
The EIC Accelerator Seal of Excellence and the EIC Transition activities Seal of Excellence are quality labels awarded to project proposals submitted by start-ups and SMEs under Horizon Europe, the EU’s research and innovation funding programme until 2027, to help these proposals find alternative funding.
Projects that were judged to deserve funding by independent experts gathered within EIC juries, but did not get it only due to budget limits, may receive such Seals of Excellence.
This now well-known quality label recognises the value of the proposal and helps other funding bodies take advantage of the Horizon Europe evaluation process.
Other news
Pan Cancer T’s potential recognised at MEET2WIN with two awards
Pan Cancer T’s strong investment potential was highlighted at MEET2WIN with two awards, giving CEO Rachel Abbott a platform to present in depth and receive direct feedback from leading European oncology experts and top pharma companies.
Extended Partnership with NecstGen
Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
4.25 Million in Seed Extension Round
Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round.
Pan Cancer T are EIT Health Catapult Finalists
On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich.
Selected as semi finalist of the EIT Health Catapult venture challenge
Pan Cancer T has been selected as semi finalist of the EIT Health Catapult venture challenge
Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Poster Presentation
Pan Cancer T is presenting preclinical data at CIMT and SITC 2023
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
“I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini. “T cell therapies hold tremendous promises for tumor patients and the development of TCR T therapies is just gaining momentum. I am convinced that Pan Cancer T will play a pioneering role in this field, as the Company is working on the main challenges in the field: identifying novel tumor antigens and leveraging engineering technology to enhance the T cells´ durability.”
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
Expanded investor syndicate strengthens the company’s financial position and investor base